Home   Logon   Mobile Site   Research and Commentary   About Us   Call 1.800.621.1675 or Email Us       Follow Us: 

Search by Ticker, Keyword or CUSIP       
 
 
First Trust Mid Cap Growth AlphaDEX® Fund (FNY)
Investment Objective/Strategy - The First Trust Mid Cap Growth AlphaDEX® Fund is an exchange-traded fund. The investment objective of the Fund is to seek investment results that correspond generally to the price and yield, before the Fund's fees and expenses, of an equity index called the Nasdaq AlphaDEX® Mid Cap Growth Index.
There can be no assurance that the Fund's investment objectives will be achieved.
Index Description According to the Index Provider
  • The Index is an "enhanced" index created and administered by Nasdaq, Inc. ("Nasdaq") which employs the AlphaDEX® stock selection methodology to select stocks from the Nasdaq US 600 Mid Cap Growth Index that meet certain criteria.
  • Nasdaq constructs the Index by ranking the eligible stocks from the Nasdaq US 600 Mid Cap Growth Index on growth factors including 3-, 6- and 12- month price appreciation, sales to price and one year sales growth, and separately on value factors including book value to price, cash flow to price and return on assets. All stocks are ranked on the sum of ranks for the growth factors and, separately, all stocks are ranked on the sum of ranks for the value factors. A stock must have data for all growth and/or value factors to receive a rank for that style.
  • Each stock receives either its growth or value score as its selection score based on its style designation as determined by Nasdaq. Only those stocks designated as growth stocks are eligible for the portfolio.
  • The top 225 stocks based on the selection score determined in the previous step comprise the "selected stocks". The selected stocks are divided into quintiles based on their rankings and the top ranked quintiles receive a higher weight within the index. The stocks are equally-weighted within each quintile.
  • The Index is reconstituted and rebalanced quarterly.
Fund Overview
TickerFNY
Fund TypeMid Cap Growth
Investment AdvisorFirst Trust Advisors L.P.
Investor Servicing AgentBank of New York Mellon Corp
CUSIP33737M102
ISINUS33737M1027
Intraday NAVFNYIV
Fiscal Year-End07/31
ExchangeNasdaq
Inception4/19/2011
Inception Price$20.17
Inception NAV$20.17
Rebalance FrequencyQuarterly
Expense Ratio0.70%
Current Fund Data (as of 10/3/2022)
Closing NAV1$55.21
Closing Market Price2$55.23
Bid/Ask Midpoint$55.20
Bid/Ask Discount0.03%
30-Day Median Bid/Ask Spread (as of 9/30/2022)30.12%
Total Net Assets$253,955,679
Outstanding Shares4,600,002
Daily Volume9,495
Average 30-Day Daily Volume32,464
Closing Market Price 52-Week High/Low$79.56 / $52.58
Closing NAV 52-Week High/Low$79.60 / $52.57
Number of Holdings (excluding cash)225
Top Holdings (as of 9/30/2022)*
Holding Percent
Shockwave Medical, Inc. 1.09%
Dillard's, Inc. (Class A) 0.93%
H&R Block, Inc. 0.91%
Texas Pacific Land Corporation 0.90%
EQT Corporation 0.89%
Murphy USA Inc. 0.89%
Sarepta Therapeutics, Inc. 0.89%
BJ's Wholesale Club Holdings, Inc. 0.88%
Carlisle Companies Incorporated 0.88%
Murphy Oil Corporation 0.88%

* Excluding cash.  Holdings are subject to change.

NAV History (Since Inception)
Past performance is not indicative of future results.
Distribution Information
Dividend per Share Amt (as of 10/4/2022)4$0.0225
30-Day SEC Yield (as of 8/31/2022)50.48%
Index Yield (as of 8/31/2022)61.16%
Fund Characteristics (as of 9/30/2022)7
Maximum Market Cap.$15,055
Median Market Cap.$5,375
Minimum Market Cap.$1,676
Price/Earnings11.79
Price/Book3.29
Price/Cash Flow8.17
Price/Sales1.60
Bid/Ask Premium/Discount (as of 10/3/2022)
  2021 Q1 2022 Q2 2022 Q3 2022
Days Traded at Premium 114 2 0 21
Days Traded at Discount 138 60 62 43
Top Sector Exposure (as of 9/30/2022)
Industrials 18.92%
Health Care 15.56%
Consumer Discretionary 13.46%
Information Technology 13.24%
Energy 12.39%
Real Estate 7.36%
Financials 6.72%
Materials 6.25%
Communication Services 2.16%
Consumer Staples 2.00%
Utilities 1.94%
Hypothetical Growth of $10,000 Since Inception (as of 9/30/2022) *